Micromet, Inc. MITI today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.
Results of the study demonstrated that blinatumomab produced durable remissions in front-line adult ALL patients at high risk of relapse. Blinatumomab is the most advanced of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in